APOE<sup>+</sup> macrophages and POSTN<sup>+</sup>CAFs form immune-exclusion niche driving immunotherapy resistance in clear-cell renal carcinoma.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 42566529.
- Also identified by DOI 10.1126/sciadv.aed0733.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Tumor immune barriers (TIBs) are spatially organized stromal-immune niches that restrict lymphocyte entry. To explain persistent immune-checkpoint blockade (ICB) resistance in clear cell renal cell carcinoma (ccRCC), we mapped TIBs and defined a peritumoral variant built from POSTN<sup>+</sup> cancer-associated fibroblasts (CAFs) interlaced with APOE<sup>+</sup> tumor-associated macrophages (TAMs). This niche excluded CD8<sup>+</sup> T cells from tumor cores, and was enriched in poor-prognosis, ICB-refractory patients. Spatial transcriptomics and single-cell profiling showed TIB regions enriched for extracellular-matrix remodeling, immunosuppressive ligand-receptor circuits, and metabolic reprogramming. Mechanistically, tumor-derived TGF-β1 activated CAFs via SMAD signaling, inducing POSTN and recruiting APOE<sup>+</sup>TAMs through integrin and chemokine axes. TAMs secreted TGF-β1 and VEGFA, amplifying stromal programs and sustaining exclusion. Blocking POSTN reprogrammed macrophages, reduced matrix-mediated suppression, and restored CD8<sup>+</sup> infiltration. In vivo, POSTN inhibition combined with ICB boosted antitumor immunity, reduced tumor burden, and reversed immunosuppressive infiltration, nominating POSTN-directed strategies to potentiate ICB.
Medical subject headings
- Kidney Neoplasms
- Carcinoma, Renal Cell
- Apolipoproteins E
- Macrophages
- Cancer-Associated Fibroblasts
- Tumor-Associated Macrophages
- Drug Resistance, Neoplasm